Abstract: The present disclosure provides a compound targeting prostate specific membrane antigen (PSMA), wherein the compound has the following structure shown in Formula (I); R1 is a compound structure targeting prostate specific membrane antigen; L1 is -(X)n-(CH2)m-(Y)q-, X and Y are independently selected from lysine, glutamic acid or a derivative structure containing lysine and glutamic acid, n is an integer from 0 to 12, m is an integer from 0 to 60, q is an integer from 0 to 12, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; L2 is -(CH2)p-, p is an integer from 0 to 30, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; and R2 is a nuclide chelating group. The present disclosure also provides a radiolabeled complex based on the structure of the compound.
Abstract: The present invention includes a probe, an assay, a method of detecting, a human NAD(P)H quinone oxidoreductase-1 (hNQO1) enzyme activity with a fluorescent probe comprising a quinone propionic acid (QPA) conjugated to dicyanoisophorone (DCP), wherein the hNQO1 reduces the probe to releases a fluorescent DCP, and a method of making the same.
Type:
Grant
Filed:
November 17, 2020
Date of Patent:
April 16, 2024
Assignee:
TEXAS TECH UNIVERSITY SYSTEM
Inventors:
Kalkunte S. Srivenugopal, Surendra R. Punganuru
Abstract: A surgical visualization and medical imaging device and related computer based imaging methods and systems are disclosed. The surgical devices of the present invention use indocyanine green dye combined with a plastic, and are used in enhanced surgical imaging in applications such as robotically assisted surgeries. A near infrared light source, such as an 805 nm laser, may be used to excite the surgical device so that the device emits 835 nm light. Both the excitation and emission wavelengths penetrate tissue and blood, and provide enhanced imaging of surgical procedures. The resulting fluorescence image allows a user to readily determine relative tissue depth, to identify tissue inhomogeneity, to detect masses or tissue irregularities, to pinpoint anatomical holes, and to visualize tears.
Type:
Grant
Filed:
February 16, 2018
Date of Patent:
April 16, 2024
Assignee:
University of Rochester
Inventors:
Paula Jaye Doyle, Jay Evan Reeder, Ronald Wesley Wood
Abstract: The present invention relates to a quantitative cellular method for the in vitro determination of the effect of an anti-CD26 ligand, preferably of an anti-CD26 monoclonal antibody, such as begelomab.
Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
April 9, 2024
Assignee:
NOVARTIS AG
Inventors:
Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
Abstract: This disclosure is directed to therapeutic compositions, and more particularly to microparticle compositions for the controlled delivery of telmisartan and actinomycin D.
Type:
Grant
Filed:
September 18, 2020
Date of Patent:
April 9, 2024
Assignees:
University of South Florida, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS
Inventors:
Subhra Mohapatra, Shyam S. Mohapatra, Eleni Markoutsa, Alejandro J. Gonzalez, Heta N. Jadhav
Abstract: Provided is a composition containing a buffer to be used at the time of labeling of a chelated targeting agent with 90Y, 153Sm, 165Dy, 165Er, 166Ho, or 177Lu. At least one kind of buffer selected from the group consisting of benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof is incorporated in a composition containing a chelated targeting agent.
Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.
Type:
Grant
Filed:
March 7, 2019
Date of Patent:
April 9, 2024
Assignee:
LUMIPHORE, INC.
Inventors:
David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
April 9, 2024
Assignee:
Clarity Pharmaceuticals Ltd
Inventors:
Paul Stephen Donnelly, Nicholas Alan Zia
Abstract: The present invention relates to an N,N?-diurea derivative represented by the following general formula (1) and a method for producing the same. In addition, the present invention relates to a thermosensitive recording material in which a thermosensitive recording layer including a basic dye which is colorless or lightly colored at room temperature and a developer capable of developing color upon contact with the basic dye by heating is provided on a base sheet, wherein the developer is the N,N?-diurea derivative represented by the following general formula (1): (wherein R2 is an alkyl group, an aralkyl group, or an aryl group; and A1 is a hydrogen atom or an alkyl group).
Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
Type:
Grant
Filed:
January 18, 2023
Date of Patent:
April 2, 2024
Assignee:
MYELOID THERAPEUTICS, INC.
Inventors:
Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
Abstract: The present disclosure relates to magnetic resonance imaging (MRI) methods comprising (i) obtaining a baseline chemical exchange saturation transfer (CEST) MRI image of a patient, (ii) administering an effective amount of a non-nutritive sweetener to the patient, and (iii) obtaining one or more test CEST MRI image of the patient subsequent to the administering step (ii); wherein the step (i) and (iii) acquisition parameters are substantially the same. The non-nutritive sweetener may include a natural or artificial sugar alcohol, polyol, or combinations or derivatives thereof.
Type:
Grant
Filed:
February 3, 2017
Date of Patent:
March 26, 2024
Assignees:
The Trustees of the University of Pennsylvania, Sidra Medicine
Inventors:
Ravinder Reddy, Mohammad Haris, Hari Hariharan, Puneet Bagga, Francesco M. Marincola, Mitchell D. Schnall
Abstract: A physiologically stable fluorophore includes a terminal moiety including a terminal reactive site that reacts with a reactive group of a substrate; a stability linker covalently bonded to the terminal moiety; and a bridge moiety covalently bonded to the stability linker such that the stability linker is interposed through chemical bonds between the bridge moiety and the terminal moiety; and a fluorescent moiety covalently bonded to the bridge moiety of the redox moiety and including: an electron bandgap mediator that is covalently bonded to the bridge moiety; a coordinate center covalently bonded to the electron bandgap mediator and that forms a Zwitterionic member with an atom in the electron bandgap mediator; and a steric hinder bonded to the electron bandgap mediator to provide steric hindrance for protection of the coordinate center.
Type:
Grant
Filed:
December 10, 2020
Date of Patent:
March 26, 2024
Assignee:
GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE
Inventors:
Jeremiah Wallace Woodcock, Jeffrey William Gilman, Douglas Matthew Fox
Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.
Type:
Grant
Filed:
July 18, 2023
Date of Patent:
March 26, 2024
Assignee:
The Johns Hopkins University
Inventors:
Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
Abstract: The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.
Type:
Grant
Filed:
October 20, 2021
Date of Patent:
March 19, 2024
Assignee:
RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventors:
Doron Shabat, Ronit Satchi-Fainaro, Nir Hananya, Ori Green, Tal Eilon
Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
Type:
Grant
Filed:
December 3, 2020
Date of Patent:
March 19, 2024
Assignee:
NOVARTIS AG
Inventors:
Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
Abstract: Combination treatment with Prussian blue nanoparticles and at least one immunotherapeutic treatment. Stable, functionalized Prussian blue nanoparticles, including those with enhanced stability under alkaline conditions, and methods of cancer, neoplasm, and tumor treatment using them, including photothermal treatment and combination immunotherapeutic treatments.
Type:
Grant
Filed:
March 8, 2017
Date of Patent:
March 19, 2024
Assignee:
Children's National Medical Center
Inventors:
Rohan Fernandes, Raymond W. Sze, Conrad Russell Y. Cruz, Anthony D. Sandler, Catherine M. Bollard, Elizabeth E. Sweeney, Juliana Cano-Mejia, Rachel Burga, Matthieu F. Dumont
Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in SPECT imaging methods.
Abstract: Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
Type:
Grant
Filed:
June 10, 2021
Date of Patent:
March 5, 2024
Assignee:
CHDI Foundation, Inc.
Inventors:
Longbin Liu, Matthew Lee, Celia Dominguez, Peter David Johnson, Catherine Jane Greenaway, Kanika Khurana, Matthew Robert Mills, Filippo Rota
Abstract: This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such as 131I-BC8 or 225Ac-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
February 27, 2024
Assignee:
ACTINIUM PHARMACEUTICALS, INC.
Inventors:
Mark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig